Format

Send to

Choose Destination
See comment in PubMed Commons below
BJOG. 2002 Sep;109(9):1056-62.

A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study.

Author information

1
Papworth Hospital, Cambridge, UK.

Abstract

OBJECTIVE:

To assess the possible benefit of hormone replacement therapy (HRT) in the secondary prevention of ischaemic heart disease.

DESIGN:

A prospective randomised trial of transdermal HRT in women with definite ischaemic heart disease.

SETTING:

A regional cardiac unit.

POPULATION:

Postmenopausal women with angiographically proven ischaemic heart disease.

METHODS:

A total of 255 postmenopausal women with angiographically proven ischaemic heart disease were recruited and randomised; 134 were treated with transdermal HRT and 121 acted as controls. The women were seen at six monthly intervals. The primary end points, which were determined by a blinded assessor, were admission to hospital with unstable angina, proven myocardial infarction or cardiac death. A total of 53 (40%) patients withdrew from the HRT group and eight (7%) from the control group. The mean duration of follow up was 30.8 months.

MAIN OUTCOME MEASURES:

Admission to hospital with unstable angina, proven myocardial infarction or cardiac death.

RESULTS:

During follow up, there were 53 primary end-point events in the HRT group and 37 in the control group. Using an intention-to-treat analysis, the primary end-point event rate was 15.4 events per 100 patient years for the HRT group compared with 11.9 for the control group (event rate ratio 1.29 (95% CI 0.84-1.95, P = 0.24)). Using a per-protocol analysis, there was an event rate ratio of 1.49 (0.93-2.36, P = 0.11) for the HRT arm compared with the control arm. Particularly during the first two years of follow up, the HRT group had a higher, but not statistically significant, event rate than the control group.

CONCLUSION:

Our findings suggest that transdermal HRT should not be commenced for the purpose of secondary prevention in postmenopausal women with angiographically proven ischaemic heart disease.

PMID:
12269682
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center